Can PacBio Finally Show the Market Its Revenue Model Actually Works?
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Pacific Biosciences reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to digest the actual numbers.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-07 | -$0.06 (-3.51%) | $0.13 (7.60%) | -$0.24 (-14.55%) | $0.17 (10.30%) |
| 2026-02-12 | +$0.00 (+0.00%) | $0.16 (8.70%) | -$0.13 (-7.07%) | $0.35 (19.02%) |
| 2025-11-05 | -$0.08 (-4.25%) | $0.19 (9.50%) | -$0.14 (-7.05%) | $0.22 (11.49%) |
| 2025-08-07 | -$0.12 (-8.70%) | $0.17 (12.32%) | +$0.09 (+7.14%) | $0.22 (17.42%) |
| 2025-05-08 | +$0.07 (+6.19%) | $0.10 (8.85%) | -$0.08 (-6.67%) | $0.11 (9.17%) |
| 2025-02-13 | +$0.12 (+8.82%) | $0.21 (15.44%) | +$0.37 (+25.00%) | $0.63 (42.57%) |
| 2024-11-07 | -$0.20 (-7.55%) | $0.34 (12.83%) | -$0.15 (-6.12%) | $0.82 (33.47%) |
| 2024-08-07 | -$0.07 (-4.38%) | $0.21 (13.12%) | +$0.14 (+9.15%) | $0.31 (20.26%) |
| Avg Abs Move | 5.42% | 11.05% | 10.34% | 20.46% |
Historical price action around PACB earnings shows significant volatility, with Day +1 moves averaging 10.34% in absolute terms and ranging as wide as 20.46% on average. The most dramatic reaction came in February 2025, when the stock surged 25.00% the day after earnings, with an intraday range of over 42%. More recently, the May 2026 report triggered a -14.55% decline on Day +1 despite a modest earnings beat, suggesting revenue disappointments or guidance concerns can override bottom-line beats.
Day 0 moves have been more muted, averaging 5.42%, which aligns with the after-close reporting schedule—most positioning happens in anticipation rather than on the day of the release itself. The pattern suggests investors should prepare for substantial volatility in the session following tomorrow's report, with historical precedent pointing to double-digit percentage swings in either direction.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 08/21/26 (DTE 17) |
| Expected Move | $0.3060 (21.25%) |
| Expected Range | $1.1340 to $1.7460 |
| Implied Volatility | 199.53% |
The options market is pricing an expected move of 21.25% through the August 21 expiration, which sits at the upper end of historical Day +1 moves (averaging 10.34%) but below the most extreme reactions like February 2025's 25% surge. This elevated implied volatility of nearly 200% suggests options traders are positioning for an outsized reaction, potentially reflecting uncertainty around revenue guidance or strategic updates beyond the quarterly EPS print.
Part 3: What Analysts Are Saying
Analyst sentiment on Pacific Biosciences remains mixed, with the consensus rating at 3.75 (between Hold and Buy) based on eight analysts. The breakdown shows 4 Strong Buys, 3 Holds, and 1 Strong Sell, indicating a polarized view where bulls see long-term potential in the company's technology platform while bears question the path to profitability and competitive sustainability.
The average price target of $2.32 implies 61% upside from the current price of $1.44, with estimates ranging from a low of $1.50 to a high of $3.00. This wide target range—spanning 100% from low to high—underscores the uncertainty around PACB's valuation, with bulls modeling aggressive revenue growth and margin expansion while bears price in continued losses and market share challenges.
Sentiment has remained unchanged over the past month, with no shifts in the ratings distribution or average recommendation. This stability suggests analysts are in wait-and-see mode ahead of earnings, looking for evidence that recent operational improvements can translate into sustained financial progress. The lack of estimate revisions—only one analyst covering the upcoming quarter—further reflects limited conviction in near-term forecasting.
Part 4: Technical Picture
The Barchart Technical Opinion currently shows a 72% Sell signal, unchanged from last week but significantly deteriorated from the 24% Sell reading a month ago. This sharp shift reflects growing technical weakness as the stock has failed to hold key support levels heading into earnings.
Timeframe Analysis:
- Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative, suggesting recent price action favors sellers
- Medium-term (50% Sell): Neutral-to-bearish reading points to consolidation with a downward bias in the intermediate timeframe
- Long-term (100% Sell): Strong sell signal reflects persistent weakness in the longer-term trend, with the stock trading well below its 200-day moving average
Trend Characteristics: The signal strength is characterized as Soft with a Weakening direction, indicating the downtrend lacks strong conviction but continues to deteriorate, creating an uncertain technical environment heading into the earnings catalyst.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $1.4280 | 50-Day MA | $1.4604 |
| 10-Day MA | $1.4030 | 100-Day MA | $1.4445 |
| 20-Day MA | $1.4455 | 200-Day MA | $1.7058 |
PACB trades at $1.44, positioned above its 5-day ($1.43) and 10-day ($1.40) moving averages, suggesting some short-term stabilization. However, the stock remains below its 20-day ($1.45), 50-day ($1.46), and 100-day ($1.44) averages, and sits significantly below the 200-day moving average of $1.71—a key long-term resistance level. This setup reflects a stock attempting to find footing after a prolonged decline, but lacking the technical momentum to suggest a sustained reversal. With the stock trading near multi-year lows and all longer-term moving averages in resistance, the technical picture is cautionary heading into tomorrow's report, leaving PACB vulnerable to further downside if results or guidance disappoint.